Galleon Pharmaceuticals Reports Positive Results From Phase I Study of GAL-021 for Treatment of Respiratory Depression

Galleon Pharmaceuticals announced that its investigational drug GAL-021 appeared to be safe and well tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.
Enhanced Online News